MST valuation of RAC, page-48

Good point. Here's the chart that DrT annotated with so far the ones he highlighted.


https://hotcopper.com.au/posts/50953426/single



I've collected some more metrics on buyout multiples ... two inhibitors acquired at peak sales multiples of 8x and 10.5x respectively (both in 2019).

The minimum peak sales estimate of this group of inhibitors is USD $1B and USD $6B for the highest and we know that Keytruda is currently at over USD $24B estimate for peak sales.

https://www.evaluate.com/vantage/ar...ng-term-forecasts-confirm-keytrudas-dominance

Average of this group of 5 is 6.2x. I think we can take the lowest 4.5x of the 2020 data as the bottom-end of a buyout multiple range. So a buyout multiple range of 4.5x to 6.2x.

Forty Seven at 4.9x was not yet approved and was based on Phase 1b data.

https://www.gilead.com/news-and-pre.../gilead-to-acquire-forty-seven-for-49-billion